Pelthos Therapeutics Inc.
PTHS
Get informed when a big investor buys or sells
+ FollowMarket Cap$18.39M
Close$
$30.18
4.3% upside
Current Fair Value
4.3% upsideUndervalued by 4.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $18.39 Million |
|---|---|
| Enterprise Value | $13.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-23.04 |
| Beta | 3.13 |
| Outstanding Shares | 3,311,742 |
Return
| Return on Equity | -146.97% |
|---|---|
| Return on Assets | -35.49% |
| Return on Invested Capital | -27.75% |
Valuation & Multiples
| P/E Ratio | -0.7 |
|---|---|
| PEG | -0.17 |
| Price to Sales | 3.62 |
| Price to Book Ratio | 2.9 |
| Enterprise Value to Revenue | 0.48 |
| Enterprise Value to EBIT | -0.4 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.02 |
| Debt to Equity | 0.77 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-2.82
Average shareholder expectationRevenue Estimate
$15.17 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 27.55%▼ 20.28% |
|---|---|
| Total Invested | $19.17M▼ 31.25% |
| Investors Holding | 17▲ 2.00% |
ESG Score
No data
About Pelthos Therapeutics Inc.
92 employees
CEO: Scott Plesha Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medic...